Scratching the Surface with a Novel Approach to Treating an Orphan Lung Disease
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Scratching the Surface with a Novel Approach to Treating an Orphan Lung Disease
-
Narrated by:
-
By:
About this listen
Bronchopulmonary dysplasia is a condition that affects preterm infants, especially those born with underdeveloped lungs who require prolonged oxygen therapy or mechanical ventilation to help them breathe after birth. It is characterized by damage and abnormal development of the lung tissue and airways, often resulting from life-saving interventions necessary for babies born very prematurely. Airway Therapeutics is developing a new class of biologics for respiratory and inflammatory diseases, starting with bronchopulmonary dysplasia. We spoke to Marc Salzberg, CEO of Airway Therapeutics, about the company’s experimental therapy zelpultide alfa, why it’s a pipeline in a product, and its development path forward.
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.